Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07544667 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Poly-L-Lactic Acid for Vulvovaginal Tissue Regeneration

StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Notable Recruitment openedv5 Show 4 more changesShow less
    • Primary completion date: Jun 2027 to Jul 2027
    • Study completion date: Jun 2028 to Jul 2028
    • Start date changed from estimate of Aug 2026 to Aug 20, 2026
    • Site details revised
  2. Minor Start date: Jul 2026 to Aug 2026v4
  3. Notable Start date: May 2026 to Jul 2026
    • Trial status changed: Recruiting → Not Yet Recruiting
    • Site details revised
    v3
  4. Notable Recruitment opened
    • Start date: Jun 2026 to May 2026
    • Site details revised
    v2
  5. Minor Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Pelvic organ prolapse (POP) is a condition characterized by descent of vaginal walls, uterus and cervix, or the perineum and causes a sensation of vaginal bulge and pelvic pressure. Millions of women in the United States are affected, and the number is expected to rise significantly in the coming decades. Current treatments either involve conservative measures or surgery. Surgery may lead to changes in vaginal topography and scar tissue, both of which impact sexual function. There are no treatment options that restore vaginal tissue strength and preserve, even optimize, sensation and blood flow to the vagina. This project will evaluate the use of poly-L-lactic acid (PLLA), an FDA-approved biostimulant for dermatologic use with an expansive safety profile over the past decade, in the treatment of anterior wall POP and its impact on sexual function. Our study will compare intravaginal injection of PLLA vs. placebo in women with stage 2 cystocele and investigate safety and preliminary efficacy of PLLA. Prior study of regenerative biologics for the vulva and vagina have shown great promise, but use of these has not been explored for POP. This randomized controlled trial has the potential to shift the paradigm of prolapse management from surgical reconstruction to regeneration. This shift will prevent the risks of surgery and has the potential to improve sexual function and quality of life by resolving POP.
Trial Details
NCT Number NCT07544667
Lead Sponsor Cassandra Kisby
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions
(from sponsor)
Pelvic Organ Prolapse (POP), Cystocele, Pelvic Floor Disorder
Related terms Cystocele, Pelvic Floor Disorders, Pelvic Organ Prolapse
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov